Age (years) |
63 ± 11 |
Gender (% female) |
20% |
Hypertension (%) |
21% |
Diabetes (%) |
10.5% |
Ischaemic HD (%) |
37% |
Average CHADS2VASC score |
2.66 ±
1.40 |
Average follow-up (months) |
28.1 ± 12.9 |
Continuous monitoring (%) |
34% |
PPM (%) |
1.3% |
ICD (%) |
14% |
BiV (%) |
17% |
Implanted loop recorder |
1.3% |
Pre ablation LVEF |
34 ± 8.7% |
DCM (%) |
47% |
Ischaemic CM (%) |
37% |
Valvular (%) |
5.2% |
Hypertrophic (%) |
0% |
Other CM (%) |
17% |
LA diameter |
46 ± 6.5 |
Paroxysmal AF (%) |
29% |
Persistent AF (%)
(Including long standing persistent)
|
71%
|
Long-standing persistent AF (%) |
26% |
Average NYHA Class |
2.37 ± 0.72 |
Medications |
Medications |
Beta-blocker (%) |
78% |
ACE Inhibitor or ARB (%) |
91% |
Spirinolactone (%) |
10% |
AAD therapy (%) |
54% |
AAD therapy + Beta blocker (%) |
89% |
Amiodarone (%) |
41% |
Sotalol (%) |
7.9% |
Flecanide (%) |
3.9% |
Vitamin K antagonist (%) |
32% |
NOAC (%) |
68% |